Clinical Trials Logo
  1. Home
  2. Breakthrough Cancer Pain
  3. NCT01693328

Patient Satisfaction and Quality of Life Impact - PecFent® — Qualipec  

Breakthrough Cancer Pain Clinical Trial

Official title:
A French, Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent® for the Treatment of Breakthrough Cancer Pain (BTPc)

Clinical Trial Summary

National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of cancer pain conditions.

• Study objectives include assessment of early treatment satisfaction.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01693328
Study type Observational
Source Archimedes Development Ltd
Contact Sylvie Allouche, MD
Phone +33155702320
Email sylvieallouchecovarrubias@archimedespharma.com
Status Recruiting
Phase N/A
Start date September 2012
View Details
See also
  Status Clinical Trial Phase
Completed NCT01946555 - Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain N/A
Recruiting NCT01698645 - Patient Satisfaction and Quality of Life Impact - PecFent® N/A
Completed NCT01936636 - Observational Registry Study of Quality of Life When Treating BTcP With Abstral N/A
Completed NCT05531422 - Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP Phase 2
Completed NCT03669263 - A Dose Titration Study of Fentanyl Buccal Soluble Film for Breakthrough Cancer Pain in Taiwan N/A
Completed NCT02899884 - Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain
Recruiting NCT03564548 - Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain Phase 2
Not yet recruiting NCT04713189 - Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain Phase 1/Phase 2
Completed NCT03895762 - Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients
Terminated NCT01439919 - A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain Phase 2
Completed NCT01045603 - Instanyl® Non-Interventional Study N/A
Recruiting NCT00822614 - Safety of Fentanyl TAIFUN Treatment Phase 3
Terminated NCT04468490 - Treatment of Breakthrough Cancer Pain According to European Guidelines